Innate lymphoid cells and disease tolerance in SARS-CoV-2 infection

Noah J. Silverstein^{1,2,3*}, Yetao Wang^{1,3*}, Zachary Manickas-Hill^{3,4}, Claudia Carbone¹, Ann Dauphin¹, Brittany P. Boribong^{5,6,7}, Maggie Loiselle⁵, Jameson Davis⁵, Maureen M. Leonard^{5,6,7}, Leticia Kuri-Cervantes^{8,9}, MGH COVID-19 Collection & Processing Team, Nuala J. Meyer¹⁰, Michael R. Betts^{8,9}, Jonathan Z. Li^{3,11}, Bruce Walker^{3,4,12,13}, Xu G. Yu^{3,4,11}, Lael M. Yonker^{5,6,7}, Jeremy Luban^{1,3,14,15}

¹Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA

²Medical Scientist Training Program, University of Massachusetts Medical School, Worcester, MA 01605, USA

³Massachusetts Consortium on Pathogen Readiness, Boston, MA, 02115

⁴Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA

⁵Massachusetts General Hospital, Mucosal Immunology and Biology Research Center, Boston, MA, USA

⁶Massachusetts General Hospital, Department of Pediatrics, Boston, MA, USA

⁷Harvard Medical School, Boston, MA, USA

⁸Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

⁹Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

¹⁰Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA

¹¹Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA

¹²Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA

¹³Department of Biology and Institute of Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA

¹⁴Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA 01605, USA

¹⁵Broad Institute of Harvard and MIT, 75 Ames Street, Cambridge, MA 02142, USA

*These authors contributed equally

Correspondence: yetao.wang@umassmed.edu (Y.W.); jeremy.luban@umassmed.edu (J.L.)

Abstract:

Risk of severe COVID-19 increases with age, is greater in males, and is associated with lymphopenia, but not with higher burden of SARS-CoV-2. It is unknown whether effects of age and sex on abundance of specific lymphoid subsets explain these correlations. This study found that the abundance of innate lymphoid cells (ILCs) decreases more than 7-fold over the human lifespan — T cell subsets decrease less than 2-fold — and is lower in males than in females. After accounting for effects of age and sex, ILCs, but not T cells, were lower in adults hospitalized with COVID-19, independent of lymphopenia. Among SARS-CoV-2-infected adults, the abundance of ILCs, but not of T cells, correlated inversely with odds and duration of hospitalization, and with severity of inflammation. ILCs were also uniquely decreased in pediatric COVID-19 and the numbers of these cells did not recover during follow-up. In contrast, children with MIS-C had depletion of both ILCs and T cells, and both cell types increased during follow-up. In both pediatric COVID-19 and MIS-C, ILC abundance correlated inversely with inflammation. Blood ILC mRNA and phenotype tracked closely with ILCs from lung. Importantly, blood ILCs produced amphiregulin, a protein implicated in disease tolerance and tissue homeostasis, and the percentage of amphiregulin-producing ILCs was higher in females than in males. These results suggest that, by promoting disease tolerance, homeostatic ILCs decrease morbidity and mortality associated with SARS-CoV-2 infection, and that lower ILC abundance accounts for increased COVID-19 severity with age and in males.

INTRODUCTION

The risk of severe COVID-19 and death in people infected with SARS-CoV-2 increases with age and is greater in men than in women (Alkhouli et al., 2020; Bunders and Altfeld, 2020; Gupta et al., 2021; Laxminarayan et al., 2020; Mauvais-Jarvis, 2020; O'Driscoll et al., 2020; Peckham et al., 2020; Richardson et al., 2020; Scully et al., 2020). These trends have been observed in people infected with SARS-CoV (Chen and Subbarao, 2007; Donnelly et al., 2003; Karlberg, 2004), or with MERS-CoV (Alghamdi et al., 2014), and in laboratory animals challenged with SARS-CoV or SARS-CoV-2 (Channappanavar et al., 2017; Leist et al., 2020). Yet, the mechanisms underlying these effects of age and sex on COVID-19 morbidity and mortality remain poorly understood.

The composition and function of the human immune system changes with age and exhibits sexual dimorphism (Darboe et al., 2020; Klein and Flanagan, 2016; Márquez et al., 2020; Patin et al., 2018; Solana et al., 2012), with consequences for survival of infection, response to vaccination, and susceptibility to autoimmune disease (Flanagan et al., 2017; Giefing-Kröll et al., 2015; Márquez et al., 2020; Mauvais-Jarvis, 2020; Patin et al., 2018; Piasecka et al., 2018). Better understanding of these effects might provide clues as to why the clinical outcome of SARS-CoV-2 infection is so variable, ranging from asymptomatic to lethal (Cevik et al., 2021; He et al., 2021; Jones et al., 2021; Lee et al., 2020; Lennon et al., 2020; Ra et al., 2021; Richardson et al., 2020; Yang et al., 2021).

Survival after infection with a pathogenic virus such as SARS-CoV-2 requires not only that the immune system control and eliminate the pathogen, but that disease tolerance mechanisms limit tissue damage caused by the pathogen or by host inflammatory responses (Ayres, 2020a; McCarville and Ayres, 2018; Medzhitov et al.,

2012; Schneider and Ayres, 2008). Research with animal models has demonstrated that genetic and environmental factors can promote host fitness without directly inhibiting pathogen replication (Ayres, 2020a; Cumnock et al., 2018; Jhaveri et al., 2007; McCarville and Ayres, 2018; Medzhitov et al., 2012; Råberg et al., 2007; Sanchez et al., 2018; Schneider and Ayres, 2008; Wang et al., 2016). Although in most cases the underlying mechanism is unknown, some of these models suggest that subsets of innate lymphoid cells (ILCs) contribute to disease tolerance (Artis and Spits, 2015; Branzk et al., 2018; Califano et al., 2018; Diefenbach et al., 2020; McCarville and Ayres, 2018; Monticelli et al., 2015, 2011).

ILCs lack clonotypic antigen receptors but overlap developmentally and functionally with T cells. Based on expression of characteristic transcription factors and specific inducible cytokines, ILCs are classified into ILC1, ILC2, and ILC3 subsets that are analogous to T_H1 , T_H2 , and T_H17 cells respectively (Artis and Spits, 2015; Cherrier et al., 2018; Vivier et al., 2018; Yudanin et al., 2019). Additionally, some ILC subsets produce the epidermal growth factor family member amphiregulin (AREG) that maintains the integrity of epithelial barriers in the lung and intestine (Branzk et al., 2018; Jamieson et al., 2013; Monticelli et al., 2015, 2011), and promotes tissue repair (Artis and Spits, 2015; Cherrier et al., 2018; Klose and Artis, 2016; Rak et al., 2016). In models of influenza infection in mice, homeostatic ILCs and exogenous AREG promote lung epithelial integrity, decrease disease severity, and increase survival, without decreasing pathogen burden (Califano et al., 2018; Jamieson et al., 2013; Monticelli et al., 2011).

Little is known about disease tolerance in the context of human infectious diseases. Interestingly, SARS-CoV-2 viral load does not reliably discriminate

symptomatic from asymptomatic infection (Cevik et al., 2021; Jones et al., 2021; Lee et al., 2020; Lennon et al., 2021; Ra et al., 2021; Yang et al., 2021). This discrepancy between SARS-CoV-2 viral load and the severity of COVID-19 is especially pronounced in children, who rarely have severe COVID-19 (Charles Bailey et al., 2020; Li et al., 2020; Lu et al., 2020; Poline et al., 2020), though viral load may be comparable to that in adults with severe COVID-19 (Heald-Sargent et al., 2020; LoTempio et al., 2021; Yonker et al., 2020). These observations suggest that age-dependent, disease tolerance mechanisms influence the severity of COVID-19. In mice, homeostatic ILCs decrease in abundance in the lung with increasing age, and lose their ability to maintain disease tolerance during influenza infection (D'Souza et al., 2019). Although the distribution of ILCs within human tissues differs from mice and is heterogeneous among individuals (Yudanin et al., 2019), human ILCs share many features with those in mice (Vivier et al., 2018) and therefore likely perform similar roles in maintaining tissue homeostasis and disease tolerance.

ILCs in peripheral blood have been reported to be depleted in individuals with severe COVID-19 (García et al., 2020; Kuri-Cervantes et al., 2020), but it is difficult to determine the extent to which ILCs are decreased independently from the overall lymphopenia associated with COVID-19 (Chen et al., 2020; Huang et al., 2020; Huang and Pranata, 2020; Zhang et al., 2020; Zhao et al., 2020), or from the reported decreases in other blood lymphoid cell populations (Kuri-Cervantes et al., 2020; Lucas et al., 2020; Mathew et al., 2020; Mudd et al., 2020; Zheng et al., 2020). In addition, assessment of lymphoid cell abundance, in the context of a disease for which age and sex are risk factors for severity, is confounded by programmed differences in lymphocyte abundance with age and sex (Márquez et al., 2020; Patin et al., 2018). The goal of this study was to

131 determine whether the abundance of any blood lymphoid cell population was altered in
132 COVID-19, independent of age, sex, and global lymphopenia, and whether abundance of
133 any lymphoid cell population correlated with clinical outcome in SARS-CoV-2 infection.

RESULTS

Characteristics of adult blood donors hospitalized for COVID-19, treated for COVID-19 as outpatients, or SARS-CoV-2-uninfected controls

The first group of blood donors in this study included SARS-CoV-2-infected adults hospitalized for severe COVID-19 (N = 40), among whom 33 (82.5%) were admitted to the ICU, 32 (80%) required intubation with mechanical ventilation, and 7 (17.5%) died (Table 1). This group had a mean age of 57.6 (range 24 to 83) and 60% were males. The second group consisted of adults infected with SARS-CoV-2 who were treated for COVID-19 as outpatients (N=51). This group had a mean age of 36.8 years (range 23-77) and was 25.5% male (Table 1). Differences between these two SARS-CoV-2-infected groups, in terms of median age ($p = 5.2 \times 10^{-8}$) and sex ratio ($p = 3.7 \times 10^{-3}$) (Fig. 1), were consistent with the established greater risk of severe COVID-19 in older individuals and in males (Alkhouli et al., 2020; Bunders and Altfeld, 2020; Gupta et al., 2021; Laxminarayan et al., 2020; Mauvais-Jarvis, 2020; O'Driscoll et al., 2020; Peckham et al., 2020; Richardson et al., 2020; Scully et al., 2020). Available information concerning ethnicity and race of the blood donors was insufficient for statistical comparisons among the groups (Supplementary Table S1). Finally, 86 adults who donated blood prior to the SARS-CoV-2 outbreak, or who were screened at a blood donation center, were included as controls for SARS-CoV-2 infection. The age of this group spanned the range of the two groups of SARS-CoV-2-infected people (mean age 50.9; range 23 to 79), and the percentage of males (55.8%) was similar to that of the group hospitalized for COVID-19 (Table 1 and Fig. 1).

Table 1: Demographic and Clinical Characteristics of Adult Blood Donor Groups

Characteristic	Healthy Control	Hospitalized	Outpatient
	N=86	N=40	N=51
Mean age (range) - years	50.9 (23-79)	57.6 (24-83)	36.8 (23-77)
Sex – number (%)			
Male	48 (55.8)	24 (60)	13 (25.5)
Female	38 (44.2)	16 (40)	38 (74.5)
Mean symptom duration at sample collection (range) – days		21.8 (5-66)	26.9 (1-61)
ICU admission – number (%)		33 (82.5)	
Intubation with mechanical ventilation – number (%)		32 (80)	
Deaths – number (%)		7 (17.5)	
Mean time hospitalized (range) – days		34.2 (4-87)	
Max lab value – mean (range)			
CRP – mg/L		228.6 (6.5-539.5)	
ESR – mm/h		89.0 (15-146)	
D-dimer – (ng/mL)		5700 (351-11923)	

157

158

159

160

161

Characteristics of pediatric blood donors with COVID-19, MIS-C, or SARS-CoV-2-uninfected controls

Children are less likely than adults to have severe disease when infected with SARS-CoV-2 despite having viral loads as high as adults (Charles Bailey et al., 2020; Heald-Sargent et al., 2020; Li et al., 2020; LoTempio et al., 2021; Lu et al., 2020; Poline et al., 2020; Yonker et al., 2020). Rarely, after SARS-CoV-2 clearance from the upper airways, children can develop severe Multisystem Inflammatory Syndrome in Children (MIS-C), a life-threatening condition distinct from COVID-19 that presents with high fevers and multiorgan injury, often including coronary aneurysms, ventricular failure, or myocarditis (Cheung et al., 2020; Feldstein et al., 2021, 2020; Licciardi et al., 2020; Riphagen et al., 2020; Verdoni et al., 2020; Whittaker et al., 2020).

The first cohort of pediatric blood donors in this study consisted of patients with COVID-19 who were treated in hospital (N=11) or as outpatients (N=8). The second cohort of pediatric blood donors was patients hospitalized for MIS-C (N=11). Seventeen SARS-CoV-2-uninfected pediatric blood donors constituted a control group. No significant differences in age or percentage of males were detected among the pediatric COVID-19, MIS-C, or pediatric control groups (Supplementary Table S2 and Fig. 1).

Fig. 1. Age and sex of control and SARS-CoV-2-infected blood donors

Age of the subjects is shown, along with the number of subjects and fraction male in each group, for adult (left) and pediatric (right) cohorts, as indicated. P-values are from pairwise, two-sided, Wilcoxon rank-sum test for ages and Fisher's exact test for fraction male, with Bonferroni correction for multiple comparisons. Adjusted P-values < 0.05 are shown.

Blood ILC abundance decreases exponentially across the lifespan and is sexually dimorphic

Lymphoid cell abundance in peripheral blood changes with age and is sexually dimorphic (Márquez et al., 2020; Patin et al., 2018). Previous studies reporting the effect of COVID-19 on the abundance of blood lymphoid cell subsets have not fully accounted for the association of age and sex with COVID-19 severity. To isolate the effect of COVID-19 on cell abundance from effects of age and sex, PBMCs were collected from 103 SARS-CoV-2-negative blood donors distributed from 2 to 79 years of age, with a nearly equal ratio of males to females. Abundance of lymphoid cell types was plotted by 20-year age groups (Fig. 2A), as well as by sex (Fig. 2B). Lymphoid cell types assessed here included CD4⁺ T cells, CD8⁺ T cells, ILCs, and FcγRIII (CD16)-positive NK cells. Like CD8⁺ T cells, NK cells kill virus-infected cells using perforin and granzyme (Artis and Spits, 2015; Cherrier et al., 2018). Additionally, by binding virus-specific immunoglobulins that target virus-infected cells for antibody-dependent cellular cytotoxicity, CD16⁺ NK cells link innate and acquired immunity (Anegón et al., 1988).

All cell types examined here were affected by age, but ILCs were the only subset with significant differences among all age groups, falling approximately 2-fold in median abundance every 20 years, with a greater than 7-fold decrease from the youngest to oldest age groups ($p = 1.64 \times 10^{-11}$) (Fig. 2A). This magnitude of decrease was unique to ILCs and corresponded inversely with the exponential increase in COVID-19 mortality with age (O'Driscoll et al., 2020) (Fig. 2C). In addition, both ILCs and CD4⁺ T cells were less abundant in males (Fig. 2B). These findings highlight the importance of accounting for effects of age and sex when assessing group differences in lymphoid cell abundance,

215 particularly in the context of a disease such as COVID-19 that disproportionately affects
216 older males (O'Driscoll et al., 2020).
217

A

B

Fig. 2. Blood ILC abundance decreases exponentially across the lifespan mirroring the mortality rate from SARS-CoV-2 infection

(A-B) Log2 abundance per million lymphocytes of the indicated lymphoid cell populations in combined pediatric and adult control data plotted by 20-year bin or by sex, as indicated. Each dot represents an individual blood donor. Boxplots represent the distribution of the data with the center line drawn through the median with the upper and lower bounds of the box at the 75th and 25th percentiles respectively. The upper and lower whiskers extend to the largest or smallest values within 1.5 x the interquartile range (IQR). P-values are from two-sided, Wilcoxon rank-sum tests with Bonferroni correction for multiple comparisons. Adjusted P-values < 0.05 are shown.

(C) Case numbers and mortality rate within the indicated age ranges for cases reported in the United States between Jan 1, 2020, and June 6, 2021.

Adults hospitalized with COVID-19 have fewer total lymphocytes even after accounting for effects of age and sex

Severe COVID-19 is associated with lymphopenia (Chen et al., 2020; Huang et al., 2020; Huang and Pranata, 2020; Zhang et al., 2020; Zhao et al., 2020) but it remains unclear if this effect is due to reduction in particular lymphoid cell subpopulations, or whether this effect is explained by the more advanced age and higher proportion of males among people with severe COVID-19. As a first step to assess the specificity of lymphocyte depletion, the effect of COVID-19 on total lymphocyte abundance was addressed with multiple linear regression. After accounting for effects of age and sex, individuals hospitalized with severe COVID-19 had 1.33-fold (95%CI: 1.49–1.19; $p = 1.22 \times 10^{-6}$) fewer total lymphocytes among PBMCs than did controls (Supplementary Table S3). Lymphocyte abundance in people infected with SARS-CoV-2 who were treated as outpatients was not different from controls (Supplementary Table S3). In addition, total lymphocytes decreased with age and were less abundant in males (Supplementary Table S3). Subsequent analyses of lymphoid cell subsets took into account the depletion in total lymphocytes associated with COVID-19 by assessing lymphoid subsets as a fraction of total lymphocytes.

After accounting for age and sex, only innate lymphoid cells are depleted in severe COVID-19

To determine whether there were independent associations between lymphoid cell subsets and COVID-19, multiple linear regression was performed on the abundance of lymphoid cell subsets, with age, sex, and group (control, hospitalized, and outpatient) as independent variables. Across all three groups of adult blood donors, CD4⁺ T cells, CD8⁺

267 T cells, and ILCs decreased with age, while CD16⁺ NK cells increased with age, and both
268 CD4⁺ T cells and ILCs were less abundant in males (Table 2 and Fig. 3A).
269

Table 2: Change in Cell Abundance Due to Age, Sex, and COVID-19 Severity

Fold difference (log2) [±95%CI]				
	CD4 ⁺ T ^a	ILC ^a	CD8 ⁺ T ^a	CD16 ⁺ NK ^a
Age	-0.012***	-0.043***	-0.009*	0.021***
	[-0.018, -0.005]	[-0.053, -0.033]	[-0.016, -0.002]	[0.010, 0.032]
Male	-0.409***	-0.334*	-0.177	0.184
	[-0.618, -0.201]	[-0.659, -0.010]	[-0.406, 0.051]	[-0.169, 0.538]
Hospitalized	0.168	-0.835***	0.227	-1.205***
	[-0.084, 0.421]	[-1.228, -0.441]	[-0.050, 0.503]	[-1.633, -0.778]
Outpatient	0.332*	-0.088	-0.023	-0.522*
	[0.082, 0.581]	[-0.478, 0.302]	[-0.298, 0.253]	[-0.948, -0.095]
R ²	0.275	0.478	0.070	0.232

* p < 0.05, ** p < 0.01, *** p < 0.001

^a per 10⁶ lymphocytes

270
271 When effects of age and sex were held constant, adults hospitalized with COVID-
272 19 had 1.78-fold fewer ILCs (95%CI: 2.34–1.36; p = 4.55 x 10⁻⁵) and 2.31-fold fewer
273 CD16⁺ natural killer (NK) cells (95%CI: 3.1–1.71; p = 1.04 x 10⁻⁷), as compared to controls
274 (Table 2 and Fig. 3B). Similar effects were also seen with ILC precursors (ILCP)
275 (Supplementary Fig. S1). Neither CD4⁺ T cells nor CD8⁺ T cells were depleted further
276 than expected for age and sex (Table 2 and Fig. 3B). As compared with controls, SARS-
277 CoV-2-infected adults with less severe COVID-19 who were treated as outpatients had

no reduction in ILCs, but 1.44-fold fewer CD16⁺ NK cells (95%CI: 1.93–1.07; $p = 0.018$), and 1.26-fold higher CD4⁺ T cells (95%CI: 1.06–1.5; $p = 9.59 \times 10^{-3}$) (Table 2 and Fig. 3B). As these analyses were performed on lymphoid cell abundance normalized to total lymphocyte number, it is possible that T cells were not lower in patients hospitalized with COVID-19 because the amount of depletion was not in excess of the change in total lymphocytes. However, the cell-type specific results remained unchanged even when the analyses were repeated using the less stringent threshold of normalizing to total PBMC number (Supplementary Table S4).

When data from an independent, previously published cohort (Kuri-Cervantes et al., 2020) were analyzed to account for total lymphocyte abundance, age, and sex, people hospitalized with acute respiratory distress syndrome due to COVID-19, had 1.7-fold fewer ILCs (95%CI: 2.38–1.22; $p = 0.002$) than controls (Supplementary Fig. S2). Also consistent with the main adult cohort studied here, ILC abundance was not significantly reduced in the group of patients with less severe disease (Supplementary Fig. S2).

Fig. 3. Innate lymphoid cells are depleted in adults hospitalized with COVID-19 and ILC abundance correlates inversely with disease severity.

(A) Effect of age (X-axis) on log2 abundance per million total lymphocytes of the indicated lymphoid cell populations (Y-axis), as determined by the regression analysis in Table 2. Each dot represents an individual blood donor, with yellow for female and blue for male. Shading represents the 95%CI. P-values are from the regression analysis for comparisons to the control group.

(B) Log2 abundance per million lymphocytes of the indicated lymphoid cell populations, shown as estimated marginal means with 95%CI, generated from the multiple linear regressions in Table 2, and averaged across age and sex. P-values represent pairwise comparisons on the estimated marginal means, adjusted for multiple comparisons with the Tukey method. Adjusted P-values < 0.05 are shown.

(C) Association of the indicated clinical parameters with log2 abundance of ILCs per million lymphoid cells. Regression lines are from simplified multiple regression models to permit visualization on a two-dimensional plane. Shading represents the 95%CI. Results of the full models accounting for effects of both age and sex, are reported in Table 4 and the text.

Odds of hospitalization in adults infected with SARS-CoV-2 increases with decreasing number of ILCs

Multiple logistic regression was used next to determine whether differences in abundance of any lymphoid cell subset was associated with odds of hospitalization in people infected with SARS-CoV-2. The adjusted odds ratio was calculated using lymphoid cell subset abundance, age, sex, and duration of symptoms at the time of blood draw, each as independent variables. Abundance of ILCs, but not of CD16⁺ NK cells, CD4⁺ T cells, or CD8⁺ T cells was associated with odds of hospitalization: the odds ratio for hospitalization, adjusted for age, sex, and symptom duration, was 0.413 (95%CI: 0.197–0.724; $p = 0.00691$), an increase of 58.7% for each 2-fold decrease in ILC abundance (Table 3).

Table 3: Odds of Hospitalization^a

Cell count ^b	Odds Ratio ^c	95% Confidence Interval	P-Value
CD4 ⁺ T	0.501	0.184–1.07	0.106
ILC	0.413	0.197–0.724	0.007
CD8 ⁺ T	1.22	0.635–2.64	0.579
CD16 ⁺ NK	0.814	0.53–1.21	0.309

^aAdjusted for age, sex, and symptom duration at time of sample collection

^bper 10⁶ lymphocytes

^cper 2-fold increase in cell population abundance

Duration of hospital stay in adults with COVID-19 increases with decreasing ILC abundance

The relationship between lymphoid cell abundance and duration of hospitalization was assessed to determine whether the association between ILC abundance and COVID-19

334 severity extended to clinical outcomes within the hospitalized adults. This relationship
335 was assessed with multiple linear regression, including age, sex, and cell abundance as
336 independent variables. Holding age and sex constant, abundance of ILCs, but not of
337 CD16⁺ NK cells, CD4⁺ T cells, or CD8⁺ T cells, was associated with length of time in the
338 hospital: each two-fold decrease in ILC abundance was associated with a 9.38 day
339 increase in duration of hospital stay (95% CI: 15.76–3.01; p = 0.0054) (Fig. 3C and Table
340 4).

Table 4: Association of cell type abundance with time in hospital and laboratory values^a

Cell count ^b	Days hospitalized	CRP (mg/L) ^c	ESR (mm/h) ^c	D-dimer (ng/mL) ^c
CD4⁺ T	-10.843	-3.335	-2.674	-1868.847*
	[-22.511, 0.825]	[-56.162, 49.492]	[-23.840, 18.492]	[-3375.630, -362.063]
ILC	-9.381**	-46.288***	-11.035*	-1098.515*
	[-15.755, -3.008]	[-71.337, -21.238]	[-21.936, -0.134]	[-1932.842, -264.188]
CD8⁺ T	3.366	32.247	15.317	486.192
	[-8.992, 15.724]	[-16.509, 81.003]	[-4.127, 34.761]	[-1049.836, 2022.221]
CD16⁺ NK	-4.775	-14.619	-5.159	-404.873
	[-11.251, 1.701]	[-44.011, 14.774]	[-16.809, 6.491]	[-1316.261, 506.516]

* p < 0.05, ** p < 0.01, *** p < 0.001

^acoefficients are for each two-fold increase in cell population abundance, adjusted for age and sex [±95%CI]

^bper 10⁶ lymphoid cells

^cMaximum lab value recorded during course of hospitalization

341 **ILC abundance correlates inversely with markers of inflammation in adults**
342 **hospitalized with COVID-19**

343 To further characterize the extent to which lymphoid cell abundance predicted COVID-19

severity, multiple regression with age, sex, and cell abundance, as independent variables, was performed on peak blood levels of inflammation markers indicative of COVID-19 severity: C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), and the fibrin degradation product D-dimer (Gallo Marin et al., 2020; Gupta et al., 2021; Luo et al., 2020; Zhang et al., 2020; Zhou et al., 2020). Holding age and sex constant, each two-fold decrease in ILC, but not in CD16⁺ NK cell, CD4⁺ T cell, or CD8⁺ T cell abundance, was associated with a 46.29 mg/L increase in blood CRP (95% CI: 71.34–21.24; $p = 6.25 \times 10^{-4}$) and 11.04 mm/h increase in ESR (95% CI: 21.94–0.13; $p = 0.047$) (Fig. 3C and Table 4). Abundance of both ILCs and CD4⁺ T cells was associated with blood levels of D-dimer, with each two-fold decrease in cell abundance associated with an increase in D-dimer by 1098.52 ng/mL (95% CI: 1932.84–264.19; $p = 0.011$) and 1868.85 ng/mL (95% CI: 3375.63–362.06; $p = 0.016$), respectively (Table 4).

ILCs are depleted in children and young adults with COVID-19 or MIS-C

Given the decline in ILC abundance with age (Fig.s 2A and 3A, and Table 2), and the inverse relationship between ILC abundance and disease severity in adults (Fig. 3C, Table 3, and Table 4), it was hypothesized that children as a group have less severe COVID-19 because ILC abundance is higher at younger ages, and that pediatric cases with symptomatic SARS-CoV-2 infection, or with MIS-C, are accompanied by significantly lower numbers of ILCs. To test these hypotheses, the abundance of lymphoid cell subsets in pediatric COVID-19 or MIS-C was compared with that from pediatric controls, using multiple linear regression with age, sex, and group as independent variables. Consistent with the findings in adults, blood ILCs in the pediatric cohort decreased with age (Table 5 and Fig. 4A), demonstrating that the decrease in ILC abundance across the lifespan is

already evident within the first two decades of life. In contrast, significant change over this age range was not detected in the abundance of CD4⁺ T cells, CD8⁺ T cells, or CD16⁺ NK cells (Table 5 and Fig 4A).

Among pediatric patients with COVID-19, no difference in abundance of the lymphoid cell subsets was associated with hospitalization (Supplementary Table S5), so all pediatric patients treated for COVID-19 were analyzed as a single group. After accounting for effects of age and sex, pediatric patients with COVID-19 had 1.69-fold fewer ILCs (95%CI: 2.73–1.04; $p = 0.034$) than controls (Fig 4A and Table 5). Neither CD4⁺ T cells, CD8⁺ T cells, nor CD16⁺ NK cells were depleted in pediatric COVID-19 patients (Fig 4A and Table 5).

As with pediatric COVID-19, ILCs were also lower in MIS-C, with 2.14-fold fewer ILCs (95%CI: 3.69–1.24; $p = 0.007$) than controls (Fig. 4A and Table 5). However, unlike pediatric COVID-19, individuals with MIS-C had reduced numbers of T cells as compared with pediatric controls, with 1.6-fold fewer CD4⁺ T cells (95%CI: 2.04–1.26; $p = 3.28 \times 10^{-4}$) and 1.42-fold fewer CD8⁺ T cells (95%CI: 1.87–1.07; $p = 0.016$) (Fig. 4A and Table 5). Depletion of T cells, then, distinguished MIS-C from both pediatric and adult COVID-19. Additionally, consistent with the finding in adults hospitalized with COVID-19 (Fig. 3C and Table 4), after accounting for effect of group, each two-fold decrease in ILC abundance in pediatric patients hospitalized with COVID-19 or MIS-C was associated with a 40.5 mg/L increase in blood CRP (95% CI: 77.87–3.13; $p = 0.035$) (Fig. 4C), and no such association was detected with CD4⁺ T cells, CD8⁺ T cells, or CD16⁺ NK cells.

Table 5: Change in Pediatric Cohort Cell Abundance Due to Age, Sex, and Group

Fold difference (log2) [$\pm$ 95%CI]				
	CD4 ⁺ T ^a	ILC ^a	CD8 ⁺ T ^a	CD16 ⁺ NK ^a
Age	-0.004	-0.083**	0.012	0.004
	[-0.027, 0.019]	[-0.135, -0.032]	[-0.014, 0.039]	[-0.060, 0.068]
Male	-0.219	-0.027	0.060	-0.343
	[-0.492, 0.054]	[-0.640, 0.586]	[-0.249, 0.370]	[-1.098, 0.413]
COVID	0.018	-0.754*	-0.088	0.416
	[-0.290, 0.327]	[-1.447, -0.061]	[-0.432, 0.257]	[-0.424, 1.257]
MIS-C	-0.678***	-1.098**	-0.503*	-0.498
	[-1.028, -0.328]	[-1.884, -0.313]	[-0.904, -0.101]	[-1.479, 0.483]
R ²	0.359	0.342	0.169	0.106

* p < 0.05, ** p < 0.01, *** p < 0.001

^aper 10⁶ lymphocytes

The above analysis of lymphoid cell subsets in pediatric COVID-19 and MIS-C was performed in comparison to pediatric controls alone. Results were essentially unchanged when multiple linear regression was repeated with combined pediatric and adult control groups (Fig. 4B, Supplementary Fig. S3, and Supplementary Table S6).

Pediatric MIS-C is distinguished from COVID-19 by recovery of ILCs during follow-up

The availability of follow-up samples in this pediatric cohort provided the opportunity to assess the abundance of lymphoid subsets after recovery from illness. To this end, a linear mixed model was fit to determine the change in ILC abundance from acute illness

to follow-up in 10 individuals (5 COVID-19 and 5 MIS-C) for whom both acute and follow-up samples were available. After accounting for effects of age, sex, and group, individuals recovering from MIS-C had a 2.39-fold increase in ILC abundance (95%CI: 1.49–3.81; $p = 6.6 \times 10^{-3}$) but there was no significant change in ILC abundance for individuals recovering from COVID-19 (Fig. 4D). Both CD4⁺ and CD8⁺ T cells, which were depleted in MIS-C but not in COVID-19, also increased during recovery from MIS-C and remained unchanged during recovery from COVID-19 (Supplementary Fig. S4).

The relationship between time to follow-up and lymphoid cell abundance was then examined for all available follow-up samples whether or not a paired sample from the acute illness was available (COVID-19, N=14; MIS-C, N=7). This analysis found no relationship between time to follow-up and abundance of any lymphoid subset, and that individuals recovering from MIS-C had 2.28-fold more ILCs (95%CI: 1.11–4.69; $p = 0.0265$) than individuals recovering from COVID-19 (Fig. 4E). There was no difference between the follow-up groups in CD4⁺ T cells, CD8⁺ T cells, or CD16⁺ NK cells (Fig. 4E). Interestingly, prior to being hospitalized with MIS-C, only one of these patients had COVID-19 symptoms and, despite low ILC abundance in the COVID-19 follow-up cohort, only 28.6% of this group had been ill enough to require hospitalization (Supplementary Table S2).

Differences between COVID-19 and MIS-C in regards to T cell depletion and ILC recovery during follow-up indicate that the underlying processes causing lower ILC abundance in these two SARS-CoV-2-associated diseases are different.

Fig. 4. ILCs are depleted in children with COVID-19 or MIS-C

424 **(A)** Effect of age (X-axis) on log2 abundance per million lymphocytes of the indicated
425 lymphoid cell populations (Y-axis), as determined by the regression analysis in Table 5.
426 Each dot represents an individual blood donor, with yellow for female and blue for male.
427 Shading represents the 95%CI. P-values are from the regression analysis for
428 comparisons to the control group.

429 **(B)** Log2 abundance per million lymphocytes of the indicated lymphoid cell populations,
430 shown as estimated marginal means with 95%CI, generated from the multiple linear
431 regressions in Table S6 that included the combined pediatric and adult control data, and
432 averaged across age and sex. P-values represent pairwise comparisons on the estimated
433 marginal means, adjusted for multiple comparisons with the Tukey method. Adjusted P-
434 values < 0.05 are shown.

435 **(C)** Association of CRP with log2 abundance of ILCs per million lymphocytes. Shading
436 represents the 95%CI. Each dot represents a single blood donor, orange for COVID-19,
437 magenta for MIS-C. P-value is for the effect of ILC abundance on CRP as determined by
438 linear regression.

439 **(D)** Log2 ILC abundance per million lymphocytes in longitudinal pairs of samples
440 collected during acute presentation and during follow-up, from individual children with
441 COVID-19 or MIS-C. Each pair of dots connected by a line represents an individual blood
442 donor. P-values are for change in ILC abundance at follow-up, as determined with a linear
443 mixed model, adjusting for age, sex, and group, and with patient as a random effect.

444 **(E)** Effect of time to follow-up (X-axis) on log2 abundance per million lymphocytes of the
445 indicated lymphoid cell populations (Y-axis). P-values are for the difference between the

COVID-19 and MIS-C follow-up groups, independent of time to follow-up as determined by linear regression. Shading represents the 95%CI.

Blood ILCs resemble homeostatic ILCs isolated from lung

In response to the observations described above regarding abundance of blood ILCs and severity of COVID-19 attempts were made to extend these studies to lung ILCs. It was not possible to obtain lung samples from people with COVID-19. However, ILCs circulate from tissues to the bloodstream in lymphatic drainage via the thoracic duct (Buggert et al., 2020) suggesting that measurement of blood ILCs could provide a surrogate for assessment of tissue-resident ILCs, including those from the lung. Furthermore, reduction in blood ILCs in people living with HIV-1 infection is paralleled by decreased ILC numbers within the lamina propria of the colon (Wang et al., 2020), and so the lower abundance of blood ILCs associated with severe COVID-19 might be paralleled by decreased abundance of homeostatic ILCs in the lung.

Given the inability to assess lung samples from people with COVID-19, RNA sequencing (RNA-Seq) was performed on blood ILCs from nine healthy controls and these data were compared to previously published RNA-Seq profiles of ILCs sorted from lung, spleen, and intestine (Ardain et al., 2019; Yudanin et al., 2019). Unbiased principal component analysis demonstrated overlap of blood ILCs with lung ILCs and clear separation from ILCs of jejunum or spleen (Fig. 5A). 355 genes were consistently differentially expressed (fold-change > 1.5, padj < 0.01) when either blood or lung ILCs were compared to ILCs from the other tissues (Fig. 5B,C). Gene ontology analysis demonstrated enrichment for terms associated with type 2 immunity (Supplementary Table S7). Genes significantly higher in both blood and lung ILCs included the ILC2-

469 defining genes GATA3 and PTGDR2 (CRTH2), as well as other genes important for ILC
470 development such as TCF7 (Yang et al., 2013) (Fig. 5B,C). As confirmation of the RNA
471 signature, TCF7- and CRTH2-encoded proteins were detected in blood ILCs by flow
472 cytometry (Fig. 6A).

Fig. 5. Blood ILCs are transcriptionally similar to lung ILCs

RNA-seq of ILCs sorted from blood of 9 SARS-CoV-2-uninfected controls in comparison to RNA-seq data of ILCs sorted from jejunum, lung, and spleen.

(A) PCA plot of first two principal components calculated from the top 250 most variable genes across all samples. Each dot represents an individual sample with blue for ILCs sorted from blood, green for lung, yellow for jejunum, and grey for spleen.

(B) Heatmap of 355 genes differentially expressed (fold-change > 1.5, padj < 0.01 as determined with DESeq2) between either blood or lung ILCs and ILCs from the other tissues.

(C) Select genes from (B) plotted as deseq2 normalized counts. Each dot represents an individual sample with blue for ILCs sorted from blood, green for lung, yellow for jejunum, and grey for spleen. Boxplots represent the distribution of the data with the center line drawn through the median with the upper and lower bounds of the box at the 75th and 25th percentiles respectively. The upper and lower whiskers extend to the largest or smallest values within 1.5 x the interquartile range (IQR).

Blood ILCs are functional ILC2s capable of producing AREG

To assess the function of blood ILCs, PBMCs were stimulated with PMA and ionomycin, and assayed by flow cytometry for production of IL-13 after intracellular cytokine staining and gating on ILCs. IL-13 was detected in the stimulated ILC population (Fig. 6B), demonstrating that the majority of blood ILCs function as ILC2s. Additionally, the blood ILCs produced amphiregulin (Fig. 6B), a protein implicated in the promotion of disease tolerance by ILCs in animal models (Branzk et al., 2018; Diefenbach et al., 2020; Jamieson et al., 2013; McCarville and Ayres, 2018; Monticelli et al., 2015, 2011).

Females have a higher fraction of amphiregulin-producing blood ILCs than do males

Given the role AREG-producing ILCs play in maintaining disease tolerance in animal models (Branzk et al., 2018; Diefenbach et al., 2020; McCarville and Ayres, 2018; Monticelli et al., 2015, 2011), sex differences in the functional capability of these ILCs could contribute to the greater risk for severe COVID-19 in males (O'Driscoll et al., 2020). To address this hypothesis, ILCs isolated from peripheral blood of controls were stimulated with PMA and ionomycin, and assayed by flow cytometry for AREG production. Consistent with the apparently lower disease tolerance in males, males had a lower median fraction of AREG⁺ ILCs than did females (P=0.018) (Fig. 6C). This difference was also reflected in a significantly lower AREG Mean Fluorescent Intensity (MFI) in males, and neither fraction of AREG⁺ ILCs nor AREG MFI was affected by age (Supplementary Fig. S5).

Fig. 6. Peripheral blood ILCs exhibit homeostatic ILC2 functions

(A-B) Flow cytometry for the indicated proteins. Cells in (A) were assayed at steady-state and cells in (B) were assayed either at steady-state or after stimulation with PMA and ionomycin, as indicated. Detection of surface proteins was performed on ILCs gated as Lin⁻CD56⁺CD127⁺ and detection of intracellular proteins was performed on ILCs gated as Lin⁻TBX21⁻CD127⁺.

(C) Percent of AREG⁺ ILCs in blood of control blood donors after stimulation with PMA and ionomycin. Each dot represents an individual blood donor. Boxplots represent the distribution of the data with the center line drawn through the median with the upper and lower bounds of the box at the 75th and 25th percentiles respectively. The upper and lower whiskers extend to the largest or smallest values within 1.5 x the interquartile range (IQR). P-value is from a two-sided, Wilcoxon rank-sum test.

DISCUSSION

The outcome of SARS-CoV-2 infection ranges from entirely asymptomatic to lethal COVID-19 (Cevik et al., 2021; He et al., 2021; Jones et al., 2021; Lee et al., 2020; Lennon et al., 2020; Ra et al., 2021; Richardson et al., 2020; Yang et al., 2021). Yet, viral load does not reliably discriminate asymptomatic from symptomatic or hospitalized populations (Cevik et al., 2021; Jones et al., 2021; Lee et al., 2020; Lennon et al., 2020; Ra et al., 2021; Yang et al., 2021). In contrast, demographic factors, including increasing age and male sex, predict worse outcome of SARS-CoV-2 infection (Alkhouli et al., 2020; Bunders and Altfeld, 2020; Gupta et al., 2021; Laxminarayan et al., 2020; Mauvais-Jarvis, 2020; O'Driscoll et al., 2020; Peckham et al., 2020; Richardson et al., 2020; Scully et al., 2020). These demographic risk factors could be due to sexual dimorphism and changes with aging in composition and function of the human immune system (Darboe et al., 2020; Klein and Flanagan, 2016; Márquez et al., 2020; Patin et al., 2018; Solana et al., 2012). Therefore it is necessary to account for effects of age and sex to determine if there are additional, independent, effects of SARS-CoV-2-associated disease.

This study collected and analyzed 245 blood samples from 177 adult and 58 pediatric patients and controls, spanning the ages of 0.7 to 83 years, with approximately equal numbers of males and females. It was therefore possible to characterize the independent effects of age, sex, COVID-19, and MIS-C on blood lymphoid cell populations. After accounting for effects of age and sex, ILCs, but not CD4⁺ or CD8⁺ T cells, were lower in individuals hospitalized with COVID-19 when compared with controls (Table 2 and Fig. 3A,B). Lower numbers of ILCs were also observed in children with COVID-19 (Table 5 and Fig. 4A,B), as well as in an independent cohort of adult patients

(Supplementary Fig. S2). Among adults infected with SARS-CoV-2, lower abundance of ILCs, but not of the other lymphoid cell subsets, was associated with increased odds of hospitalization, longer duration of hospitalization, and higher blood level of factors associated with systemic inflammation, including CRP (Tables 3 and 4, and Fig. 3C). This inverse relationship between ILC abundance and CRP was also evident in children with COVID-19 or MIS-C (Fig. 4C).

The identification of reduced ILC numbers as uniquely related to COVID-19 severity is important as these cells mediate disease tolerance in animal models (Artis and Spits, 2015; Branzk et al., 2018; Califano et al., 2018; Diefenbach et al., 2020; McCarville and Ayres, 2018; Monticelli et al., 2015, 2011). The results here therefore indicate that loss of ILCs from blood correlates with loss of ILC-associated homeostatic functions, thereby allowing more severe COVID-19. Although this study examined circulating blood lymphoid cells, and does not provide direct information about processes occurring within tissues, transcriptional and functional characterization of blood ILCs demonstrated that these cells are similar to ILCs isolated from lung tissue (Fig. 5). Human ILCs circulate in lymphatic fluid draining from the tissues to the blood via the thoracic duct (Buggert et al., 2020), raising the possibility that some ILCs in the blood originate from, or traffic to, lung tissue. Further characterization of these blood ILCs showed that they are functional ILC2s capable of producing the protein AREG (Fig. 6A,B). Given the tissue homeostatic role AREG plays in animal models of disease tolerance (Branzk et al., 2018; Diefenbach et al., 2020; Jamieson et al., 2013; McCarville and Ayres, 2018; Monticelli et al., 2015, 2011), the discovery here that males have a smaller fraction than females of blood ILCs capable of producing AREG (Fig. 6C) could explain why males are at greater risk of death

from SARS-CoV-2 infection (O'Driscoll et al., 2020). This sexual dimorphism in ILC function would be amplified further by the lower overall abundance of ILCs in males (Fig. 2B and Table 3).

Although the inverse relationship between the number of blood ILCs and severity of COVID-19 suggests that loss of ILC homeostatic function results in breakdown of disease tolerance (Arpaia et al., 2015; Artis and Spits, 2015; Branzk et al., 2018; Diefenbach et al., 2020; McCarville and Ayres, 2018; Monticelli et al., 2015, 2011), this observational study cannot determine whether ILC depletion preceded SARS-CoV-2 infection or whether ILC numbers are depleted as a consequence of SARS-CoV-2 infection. However, several observations support the hypothesis that individuals with lower ILC numbers at the time of SARS-CoV-2 infection are at greater risk of developing severe disease. ILC numbers in uninfected controls decrease exponentially with age; this decrease is much larger than that seen with other lymphoid cell types (Fig. 2A), and much more closely mirrors the exponential increase in COVID-19 mortality with age (O'Driscoll et al., 2020) (Fig. 2C). In addition, the greater risk of COVID-19 mortality in males (O'Driscoll et al., 2020) correlates with lower abundance of blood ILCs (Fig. 2B and Table 3) and smaller fraction of ILCs capable of producing AREG (Fig. 6C). Further supporting this hypothesis is the observation that conditions independently associated with lower ILC abundance, such as HIV-1 infection (Kløverpris et al., 2016; Wang et al., 2020) and obesity (Brestoff et al., 2015; Yudanin et al., 2019), increase the risk for worse outcomes from SARS-CoV-2 infection (Biccard et al., 2021; Kompaniyets, 2021; Tesoriero et al., 2021).

In contrast to individuals with COVID-19, children with MIS-C had lower numbers

of T cells as well as ILCs (Table 5 and Fig. 4A,B), and longitudinal follow-up samples for pediatric COVID-19 and MIS-C patients showed persistence of low ILC numbers after COVID-19, but normalization of all depleted cell types after recovery from MIS-C (Fig. 4D,E and Supplementary Fig. S4). These differences imply that the reversible lymphopenia in MIS-C is due to different underlying processes than the more specific and persistent lower ILC abundance seen in individuals with COVID-19. This difference is made more interesting by the fact that none of the children with MIS-C had required hospitalization for COVID-19 and only one experienced any COVID-19 symptoms. The other children with MIS-C were therefore unaware that they had been infected. It is possible that children with pre-existing lower ILC numbers are at risk of developing COVID-19 if infected with SARS-CoV-2, while other factors such as prolonged exposure to SARS-CoV-2 antigens in the gastrointestinal tract (Yonker et al., 2021), or rare inborn errors of immunity (Sancho-Shimizu et al., 2021), promote inflammatory processes in MIS-C that drive nonspecific lymphoid cell depletion, which ultimately normalizes after recovery.

Although ILC depletion and recovery has been reported in rheumatoid arthritis (Rauber et al., 2017), inflammation-driven ILC-depletion is not necessarily reversible, as ILCs appear permanently depleted after HIV-1 infection, possibly by high levels of common γ -chain cytokines during acute infection (Wang et al., 2020). Better understanding of the processes that drive down ILC abundance in populations susceptible to COVID-19 could potentially allow for development of interventions that increase ILC abundance and restore homeostatic disease tolerance mechanisms.

In conclusion, considering the established homeostatic function of ILCs (Artis and

Spits, 2015; Branzk et al., 2018; Klose and Artis, 2016; Monticelli et al., 2015, 2011) and presumed non-immunologic, host adaptive responses necessary to survive pathogenic infection (López-Otín and Kroemer, 2021; McCarville and Ayres, 2018; Medzhitov et al., 2012; Schneider and Ayres, 2008), the findings reported here support the hypothesis that loss of disease tolerance mechanisms attributable to ILCs increase the risk of morbidity and mortality with SARS-CoV-2 infection. The findings of this observational study warrant establishment of prospective cohorts to determine whether abundance of ILCs or of other lymphoid cell subsets associated with disease tolerance (Arpaia et al., 2015; Artis and Spits, 2015; Branzk et al., 2018; Diefenbach et al., 2020; McCarville and Ayres, 2018; Monticelli et al., 2015, 2011), predict clinical outcome for infection with SARS-CoV-2 or other lethal pathogens. Understanding the mechanisms that allow an individual to tolerate high-level viral replication without experiencing symptoms, and how these mechanisms can fail and thereby allow for progression to severe disease, will provide the foundation for development of therapeutic interventions that maintain health and improve survival of pathogenic viral infection (Ayres, 2020b).

Materials and Methods

Data availability

The data that support the findings of this study are available within the manuscript and in its supplementary information files. Bulk RNA-seq datasets generated here can be found at: NCBI Gene Expression Omnibus (GEO): GSE168212. Bulk RNA-seq data generated by previously-published studies are available from NCBI GEO: GSE131031 and GSE126107. This study did not generate unique code. Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

Peripheral blood PBMCs

As part of a COVID-19 observational study, peripheral blood samples were collected from 91 adults with SARS-CoV-2 infection at the Massachusetts General Hospital and affiliated outpatient clinics. Request for access to coded patient samples was reviewed by the Massachusetts Consortium for Pathogen Readiness (<https://masscpr.hms.harvard.edu/>), and approved by the University of Massachusetts Medical School IRB (protocol #H00020836). Pediatric participants with COVID-19 or MIS-C were enrolled in the Massachusetts General Hospital Pediatric COVID-19 Biorepository (MGB IRB # 2020P000955); healthy pediatric controls were enrolled in the Pediatric Biorepository (MGB IRB # 2016P000949). Samples were collected after obtaining consent from the patient if 18 years or older, or from the parent/guardian, plus assent when appropriate. Demographic, laboratory, and clinical outcome data were included with the coded samples. Samples from 86 adult blood donors and 17 pediatric blood donors, either

collected prior to the SARS-CoV-2 outbreak, or from healthy individuals screened at a blood bank, were included as controls.

Human mononuclear cell isolation

Human peripheral blood was diluted in an equal volume of RPMI-1640 (Gibco), overlaid on Lymphoprep (STEMCELL, 07851), and centrifuged at 500 x g at room temperature for 30 minutes. Mononuclear cells were washed 3 times with MACS buffer (0.5% BSA and 2 mM EDTA in PBS) and frozen in FBS containing 10% DMSO.

Flow cytometry

Peripheral blood mononuclear cells (PBMCs) were first stained with Live and Dead violet viability kit (Invitrogen, L-34963). To detect surface molecules, cells were stained in MACS buffer with antibodies (Supplementary Table S8) for 30 min at 4°C in the dark. To detect IL-13 or AREG, cells were stimulated with PMA and ionomycin (eBioscience, 00-4970-03) for 3 hours with Brefeldin A and Monensin (eBioscience, 00-4980-03) present during the stimulation. To detect transcription factors or cytokines, cells were fixed and permeabilized using Foxp3 staining buffer kit (eBioscience, 00-5523-00), then intracellular molecules were stained in permeabilization buffer with antibodies. Cells were detected on a BD Celesta flow cytometer using previously established gating strategies (Wang et al., 2020). Cell subsets were identified using FlowJo™ software (Becton, Dickson and Company). Representative gating strategies are shown in Fig. S6.

Bulk RNA-Seq Library preparation of PBMC ILCs

The sequencing libraries were prepared using CEL-Seq2 (Hashimshony et al., 2016). RNA from sorted cells was extracted using TRIzol reagent (ThermoFisher, 15596018). 10 ng RNA was used for first strand cDNA synthesis using barcoded primers (the specific primers for each sample were listed in Supplementary Table S9). The second strand was synthesized by NEBNext Second Strand Synthesis Module (NEB, E6111L). The pooled dsDNA was purified with AMPure XP beads (Beckman Coulter, A63880), and subjected to in vitro transcription (IVT) using HiScribe T7 High Yield RNA Synthesis Kit (NEB, E2040S), then treated with ExoSAP-IT (Affymetrix, 78200). IVT RNA was fragmented using RNA fragmentation reagents (Ambion), and underwent another reverse transcription step using random hexamer RT primer-5'-GCC TTG GCA CCC GAG AAT TCC ANN NNN N-3' to incorporate the second adapter. The final library was amplified with indexed primers: RP1 and RPI1 (Supplementary Table S9), and the bead purified library was quantified with 4200 TapeStation (Agilent Technologies), and paired-end sequenced on Nextseq 500 V2 (Illumina), Read 1: 15 cycles; index 1: 6 cycles; Read 2: 60 cycles.

RNA-seq analyses

Pooled reads from PBMC ILCs were separated by CEL-Seq2 barcodes, and demultiplexed reads from RNA-seq of ILCs from lung (Ardain et al., 2019), spleen and intestine (Yudanin et al., 2019), were downloaded from GSE131031 and GSE126107. Within the DolphinNext RNA-seq pipeline (Revision 4) (Yukselen et al., 2020), reads were aligned to the hg19 genome using STAR (version 2.1.6) (Dobin et al., 2013) and counts

of reads aligned to RefSeq genes were quantified using RSEM (version 1.3.1) (Li and Dewey, 2011). Normalized transcript abundance in the form of TPMs were used to filter out low abundance transcripts with an average of <3 TPMs across libraries. RSEM-generated expected counts were normalized and differential analysis was performed using DEseq2 (Love et al., 2014) in R, with significant genes defined as a greater than 1.5-fold difference and an adjusted p-value <0.01. GO Enrichment Analysis was performed in R using the enrichGO function in the clusterProfiler R package (Yu et al., 2012). Data were transformed using vsd within DEseq2 both for the heatmap visualization with ComplexHeatmap (Gu et al., 2016) and for principal component analysis (PCA) with prcomp on the top 250 most variable genes. Normalized counts were generated for plotting using the counts command in Deseq2.

Statistical analysis and data visualization

Data were prepared for analysis with tidyverse packages (Wickham et al., 2019) and visualized using the ggplot2 (Wickham, 2016), ggpubr (Kassambara, 2020), and ComplexHeatmap (Gu et al., 2016) packages, within the R computer software environment (version 4.0.2) (R Core Team, 2020). Group differences were determined with pairwise, two-sided, Wilcoxon rank-sum tests, or Fisher's exact test, as indicated, with Bonferroni correction for multiple comparisons. Multiple linear regression analyses were performed with dependent and independent variables as indicated in the text, using the lm function in R. Pairwise group comparisons on estimated marginal means generated from multiple linear regression were performed using the emmeans package (Lenth, 2020) in R, with multiple comparison correction using the Tukey adjustment. Multiple logistic regressions were performed using the glm function in R. Longitudinal

follow-up analyses on pediatric COVID-19 and MIS-C was performed with linear mixed-effect models using lme4 (Bates et al., 2015) in R with the equation: $\log_2(\text{lymphoid cell abundance}) \sim \text{Age} + \text{Sex} + \text{Group} + \text{Group:Follow_up} + (1|\text{Patient_ID})$. This model tested the effect of followup on ILC abundance in the pediatric COVID-19 and MIS-C groups while accounting for age, sex, and group. Statistical significance was determined with lmerTest (Kuznetsova et al., 2017) in R, using the Satterthwaite's degrees of freedom method. $p < 0.05$ was considered significant. United States SARS-CoV-2 infection and mortality data were downloaded from (CDC Case Surveillance Task Force, 2020) and cases with age group and outcome available were plotted by age group as indicated. Mortality rate was calculated by dividing the number of fatal cases by the total number of cases with known outcome in each age group as indicated.

REFERENCES

- Alghamdi IG, Hussain II, Almalki SS, Alghamdi MS, Alghamdi MM, El-Sheemy MA. 2014. The pattern of Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive epidemiological analysis of data from the Saudi Ministry of Health. *Int J Gen Med* **7**:417.
- Alkhouli M, Nanjundappa A, Annie F, Bates MC, Bhatt DL. 2020. Sex Differences in Case Fatality Rate of COVID-19: Insights From a Multinational Registry. *Mayo Clin Proc* **95**:1613–1620.
- Anegon I, Cuturi MC, Trinchieri G, Perussia B. 1988. Interaction of Fc receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells. *J Exp Med* **167**:452–472.
- Ardain A, Domingo-Gonzalez R, Das S, Kazer SW, Howard NC, Singh A, Ahmed M, Nhamoyebonde S, Rangel-Moreno J, Ogongo P, Lu L, Ramsuran D, de la Luz Garcia-Hernandez M, K. Ulland T, Darby M, Park E, Karim F, Melocchi L, Madansein R, Dullabh KJ, Dunlap M, Marin-Agudelo N, Ebihara T, Ndung'u T, Kaushal D, Pym AS, Kolls JK, Steyn A, Zúñiga J, Horsnell W, Yokoyama WM, Shalek AK, Kløverpris HN, Colonna M, Leslie A, Khader SA. 2019. Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis. *Nature* **570**:528–532.
- Arpaia N, Green JA, Molledo B, Arvey A, Hemmers S, Yuan S, Treuting PM, Rudensky AY. 2015. A Distinct Function of Regulatory T Cells in Tissue Protection. *Cell* **162**:1078–1089.

783 Artis D, Spits H. 2015. The biology of innate lymphoid cells. *Nature* **517**:293–301.

784 Ayres JS. 2020a. The Biology of Physiological Health. *Cell* **181**:250–269.

785 Ayres JS. 2020b. Surviving COVID-19: A disease tolerance perspective. *Sci Adv*
786 **6**:eabc1518.

787 Bates D, Mächler M, Bolker B, Walker S. 2015. Fitting Linear Mixed-Effects Models
788 Usinglme4. *Journal of Statistical Software*. doi:10.18637/jss.v067.i01

789 Biccard BM, Gopalan PD, Miller M, Michell WL, Thomson D, Ademuyiwa A, Aniteye E,
790 Calligaro G, Chaibou MS, Dhufera HT, Elfagieh M, Elfiky M, Elhadi M, Fawzy M,
791 Fredericks D, Gebre M, Bayih AG, Hardy A, Joubert I, Kifle F, Kluyts H-L, Macleod
792 K, Mekonnen Z, Mer M, Morais A, Msosa V, Mulwafu W, Ndonga A, Ngumi Z,
793 Omigbodun A, Owoo C, Paruk F, Piercy JL, Scribante J, Seman Y, Taylor E, van
794 Straaten D, Elfiky M, Fawzy M, Awad A, Hussein H, Shaban M, Elbadawy M,
795 Elmehrath AO, Cordie A, Elganainy M, El-Shazly M, Essam M, Abdelwahab OA,
796 Ali A, Hussein AM, Kamel EZ, Monib FA, Ahmed I, Saad MM, Al-Quossi MA,
797 Rafaat N, Galal I, Labib B, Omran DO, Fawzy M, Elfiky M, Azzam Ahmed, Azab
798 M, Tawheed A, Gamal M, El Kassas M, Azzam Aml, Ahmed N, NasrEldin Y,
799 Abdewahab O, Elganainy M, Elmandouh O, Dhufera HT, MeGebre M, Bayih AG,
800 Kifle F, Mekonnen Z, Seman Y, Addisie A, Eshete A, Kifle F, Desita K, Araya H,
801 Agidew Y, Andabo AD, Tesfaye E, Yesuf EA, Hailemariam G, Mohammed MS,
802 Gebremedhin Y, Taye Y, Mebrate TA, Gemechu TB, Bedane TT, Abera ET,
803 Teshome A, Ernest Aniteye EA, Christian Owoo CO, Doku A, Owoo C, Afriyie-
804 Mensah JS, Lawson A, Owoo C, DYaw Sottie DA, Addae E, Ernest Ofosu-Appiah
805 EO-A, William Obeng WO, Ndonga A, Ngumi Z, Ndonga A, Mugera A, Bitta C,

Elfagieh M, Elhadi M, Huwaysh MA, Yahya MMA, Mohammed AAK, Majeed AAM, Mohammed AEM, Majeed E, Abusalama AA, Altayr E, Abubaker T, Alkaseek AM, Abdulhafith B, Alziyituni Z, Gamra MF, Anaiba MM, Khel S, Abdelkabir M, Abdeewi S, Adam S, Alhadi A, Alsoufi A, Hassan M, Msherghi A, Bouhuwaish AEM, Msosa V, Mulwafu W, Masoo F, Chikumbanje SS, Mabedi D, Morais A, Carlos A, Morais A, Lorenzoni C, Mambo J, Isabel Chissaque I, Mouzinho Saide M, Chaibou MS, Mamane M, Amadou F, Adesoji Ademuyiwa AA, Akinyinka Omigbodun AO, Adeyeye A, Akinmade A, Momohsani Y, Bamigboye J, Orshio D, Isamade ES, Embu H, Nuhu S, Ojiakor S, Nuhu A, Fowotade A, Sanusi A, Osinaike B, Idowu O, Amali AO, Ibrahim S, Adamu AA, Kida I, Otokwala J, Essam M, Alagbe-Briggs O, Ojum S, Fathima Paruk FP, Juan Scribante JS, Mdladla A, Mabotja T, Naidoo R, Matos-Puig R, Ramkillawan A, Smith M, Arnold-Day C, Thomson D, Calligaro G, Joubert I, Jagga J, Piercy J, Michell L, Devenish L, Miller M, Fernandes N, Gopalan D, Pershad S, Grabowski N, Rammego M, Zwane S, Dhlamini ME, Neuhoff M, Fodo T, Usenbo A, Mrara B, Kabambi F, Cloete E, De Caires L, Dickerson R, Louw C, Theron A, Herselman R, Badenhorst J, Moletsane G, Loots H, Paruk F, Chausse J, Neuhoff M, Sebastian M, Grabowski N, Rheeder P, van Houghenhouck-Tulleken W, Snyman C, Adeleke D, Esterhuizen J, de Man L, Mosola M, van der Linde P, Swart R, Maasdorp S, Martins T, Govender V. 2021. Patient care and clinical outcomes for patients with COVID-19 infection admitted to African high-care or intensive care units (ACCCOS): a multicentre, prospective, observational cohort study. *Lancet* **397**:1885–1894.

Branzk N, Gronke K, Diefenbach A. 2018. Innate lymphoid cells, mediators of tissue homeostasis, adaptation and disease tolerance. *Immunol Rev* **286**:86–101.

Brestoff JR, Kim BS, Saenz SA, Stine RR, Monticelli LA, Sonnenberg GF, Thome JJ, Farber DL, Lutfy K, Seale P, Artis D. 2015. Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity. *Nature* **519**:242–246.

Buggert M, Vella LA, Nguyen S, Wu VH, Chen Z, Sekine T, Perez-Potti A, Maldini CR, Manne S, Darko S, Ransier A, Kuri-Cervantes L, Japp AS, Brody IB, Ivarsson MA, Gorin J-B, Rivera-Ballesteros O, Hertwig L, Antel JP, Johnson ME, Okoye A, Picker L, Vahedi G, Sparrelid E, Llewellyn-Lacey S, Gostick E, Sandberg JK, Björkström N, Bar-Or A, Dori Y, Naji A, Canaday DH, Laufer TM, Wells AD, Price DA, Frank I, Douek DC, Wherry EJ, Itkin MG, Betts MR. 2020. The Identity of Human Tissue-Emigrant CD8⁺ T Cells. *Cell* **183**:1946-1961.e15.

Bunders MJ, Altfeld M. 2020. Implications of Sex Differences in Immunity for SARS-CoV-2 Pathogenesis and Design of Therapeutic Interventions. *Immunity* **53**:487–495.

Califano D, Furuya Y, Roberts S, Avram D, McKenzie ANJ, Metzger DW. 2018. IFN- γ increases susceptibility to influenza A infection through suppression of group II innate lymphoid cells. *Mucosal Immunol* **11**:209–219.

CDC Case Surveillance Task Force. 2020. COVID-19 Case Surveillance Public Use Data.

Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. 2021. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. *The Lancet Microbe* **2**:e13–e22.

851 Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S. 2017. Sex-
852 Based Differences in Susceptibility to Severe Acute Respiratory Syndrome
853 Coronavirus Infection. *J Immunol* **198**:4046–4053.

854 Charles Bailey L, Razzaghi H, Burrows EK, Timothy Bunnell H, Camacho PEF, Christakis
855 DA, Eckrich D, Kitzmiller M, Lin SM, Magnusen BC, Newland J, Pajor NM, Ranade
856 D, Rao S, Sofela O, Zahner J, Bruno C, Forrest CB. 2020. Assessment of 135 794
857 Pediatric Patients Tested for Severe Acute Respiratory Syndrome Coronavirus 2
858 Across the United States. *JAMA Pediatr*. doi:10.1001/jamapediatrics.2020.5052

859 Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang Xiaoyun, Chen H, Yu
860 H, Zhang Xiaoping, Zhang M, Wu S, Song J, Chen T, Han M, Li S, Luo X, Zhao J,
861 Ning Q. 2020. Clinical and immunological features of severe and moderate
862 coronavirus disease 2019. *J Clin Invest* **130**:2620–2629.

863 Chen J, Subbarao K. 2007. The Immunobiology of SARS. *Annu Rev Immunol* **25**:443–
864 472.

865 Cherrier DE, Serafini N, Di Santo JP. 2018. Innate Lymphoid Cell Development: A T Cell
866 Perspective. *Immunity* **48**:1091–1103.

867 Cheung EW, Zachariah P, Gorelik M, Boneparth A, Kernie SG, Orange JS, Milner JD.
868 2020. Multisystem Inflammatory Syndrome Related to COVID-19 in Previously
869 Healthy Children and Adolescents in New York City. *JAMA* **324**:294–296.

870 Cumnock K, Gupta AS, Lissner M, Chevee V, Davis NM, Schneider DS. 2018. Host
871 Energy Source Is Important for Disease Tolerance to Malaria. *Curr Biol* **28**:1635-
872 1642.e3.

873 Darboe A, Nielsen CM, Wolf A-S, Wildfire J, Danso E, Sonko B, Bottomley C, Moore SE,
874 Riley EM, Goodier MR. 2020. Age-Related Dynamics of Circulating Innate
875 Lymphoid Cells in an African Population. *Front Immunol* **11**:594107.

876 Diefenbach A, Gnafakis S, Shomrat O. 2020. Innate Lymphoid Cell-Epithelial Cell
877 Modules Sustain Intestinal Homeostasis. *Immunity* **52**:452–463.

878 Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M,
879 Gingeras TR. 2013. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics*
880 **29**:15–21.

881 Donnelly CA, Ghani AC, Leung GM, Hedley AJ, Fraser C, Riley S, Abu-Raddad LJ, Ho
882 L-M, Thach T-Q, Chau P, Chan K-P, Lam T-H, Tse L-Y, Tsang T, Liu S-H, Kong
883 JHB, Lau EMC, Ferguson NM, Anderson RM. 2003. Epidemiological determinants
884 of spread of causal agent of severe acute respiratory syndrome in Hong Kong.
885 *Lancet* **361**:1761–1766.

886 D’Souza SS, Shen X, Fung ITH, Ye L, Kuentzel M, Chittur SV, Furuya Y, Siebel CW,
887 Maillard IP, Metzger DW, Yang Q. 2019. Compartmentalized effects of aging on
888 group 2 innate lymphoid cell development and function. *Aging Cell*.
889 doi:10.1111/accel.13019

890 Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, Newburger
891 JW, Kleinman LC, Heidemann SM, Martin AA, Singh AR, Li S, Tarquinio KM, Jaggi
892 P, Oster ME, Zackai SP, Gillen J, Ratner AJ, Walsh RF, Fitzgerald JC, Keenaghan
893 MA, Alharash H, Doymaz S, Clouser KN, Giuliano JS Jr, Gupta A, Parker RM,
894 Maddux AB, Havalad V, Ramsingh S, Bukulmez H, Bradford TT, Smith LS,
895 Tenforde MW, Carroll CL, Riggs BJ, Gertz SJ, Daube A, Lansell A, Coronado

Munoz A, Hobbs CV, Marohn KL, Halasa NB, Patel MM, Randolph AG, Overcoming COVID-19 Investigators, CDC COVID-19 Response Team. 2020. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. *N Engl J Med* **383**:334–346.

Feldstein LR, Tenforde MW, Friedman KG, Newhams M, Rose EB, Dapul H, Soma VL, Maddux AB, Mourani PM, Bowens C, Maamari M, Hall MW, Riggs BJ, Giuliano JS Jr, Singh AR, Li S, Kong M, Schuster JE, McLaughlin GE, Schwartz SP, Walker TC, Loftis LL, Hobbs CV, Halasa NB, Doymaz S, Babbitt CJ, Hume JR, Gertz SJ, Irby K, Clouser KN, Cvijanovich NZ, Bradford TT, Smith LS, Heidemann SM, Zackai SP, Wellnitz K, Nofziger RA, Horwitz SM, Carroll RW, Rowan CM, Tarquinio KM, Mack EH, Fitzgerald JC, Coates BM, Jackson AM, Young CC, Son MBF, Patel MM, Newburger JW, Randolph AG, Overcoming COVID-19 Investigators. 2021. Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19. *JAMA*. doi:10.1001/jama.2021.2091

Flanagan KL, Fink AL, Plebanski M, Klein SL. 2017. Sex and Gender Differences in the Outcomes of Vaccination over the Life Course. *Annu Rev Cell Dev Biol* **33**:577–599.

Gallo Marin B, Aghagoli G, Lavine K, Yang L, Siff EJ, Chiang SS, Salazar-Mather TP, Dumenco L, Savaria MC, Aung SN, Flanigan T, Michelow IC. 2020. Predictors of COVID-19 severity: A literature review. *Rev Med Virol* e2146.

García M, Kokkinou E, Carrasco García A, Parrot T, Palma Medina LM, Maleki KT, Christ W, Varnaité R, Filipovic I, Ljunggren H-G, Others. 2020. Innate lymphoid cell

919 composition associates with COVID-19 disease severity. *Clinical & translational*
920 *immunology* **9**:e1224.

921 Giefing-Kröll C, Berger P, Lepperdinger G, Grubeck-Loebenstien B. 2015. How sex and
922 age affect immune responses, susceptibility to infections, and response to
923 vaccination. *Aging Cell* **14**:309–321.

924 Gu Z, Eils R, Schlesner M. 2016. Complex heatmaps reveal patterns and correlations in
925 multidimensional genomic data. *Bioinformatics* **32**:2847–2849.

926 Gupta RK, Harrison EM, Ho A, Docherty AB, Knight SR, van Smeden M, Abubakar I,
927 Lipman M, Quartagno M, Pius R, Buchan I, Carson G, Drake TM, Dunning J,
928 Fairfield CJ, Gamble C, Green CA, Halpin S, Hardwick HE, Holden KA, Horby PW,
929 Jackson C, Mclean KA, Merson L, Nguyen-Van-Tam JS, Norman L, Olliaro PL,
930 Pritchard MG, Russell CD, Scott-Brown J, Shaw CA, Sheikh A, Solomon T, Sudlow
931 C, Swann OV, Turtle L, Openshaw PJM, Baillie JK, Semple MG, Noursadeghi M,
932 ISARIC4C Investigators. 2021. Development and validation of the ISARIC 4C
933 Deterioration model for adults hospitalised with COVID-19: a prospective cohort
934 study. *Lancet Respir Med*. doi:10.1016/S2213-2600(20)30559-2

935 Hashimshony T, Senderovich N, Avital G, Klochendler A, de Leeuw Y, Anavy L, Gennert
936 D, Li S, Livak KJ, Rozenblatt-Rosen O, Dor Y, Regev A, Yanai I. 2016. CEL-Seq2:
937 sensitive highly-multiplexed single-cell RNA-Seq. *Genome Biol* **17**:77.

938 He J, Guo Y, Mao R, Zhang J. 2021. Proportion of asymptomatic coronavirus disease
939 2019: A systematic review and meta-analysis. *J Med Virol* **93**:820–830.

940 Heald-Sargent T, Muller WJ, Zheng X, Rippe J, Patel AB, Kociolek LK. 2020. Age-Related
941 Differences in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus

942 2 (SARS-CoV-2) Levels in Patients With Mild to Moderate Coronavirus Disease
943 2019 (COVID-19). *JAMA Pediatr* **174**:902–903.

944 Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu
945 T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J,
946 Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. 2020. Clinical features of patients
947 infected with 2019 novel coronavirus in Wuhan, China. *Lancet* **395**:497–506.

948 Huang I, Pranata R. 2020. Lymphopenia in severe coronavirus disease-2019 (COVID-
949 19): systematic review and meta-analysis. *J Intensive Care Med* **8**:36.

950 Jamieson AM, Pasman L, Yu S, Gamradt P, Homer RJ, Decker T, Medzhitov R. 2013.
951 Role of tissue protection in lethal respiratory viral-bacterial coinfection. *Science*
952 **340**:1230–1234.

953 Jhaveri KA, Trammell RA, Toth LA. 2007. Effect of environmental temperature on sleep,
954 locomotor activity, core body temperature and immune responses of C57BL/6J
955 mice. *Brain Behav Immun* **21**:975–987.

956 Jones TC, Biele G, Mühlemann B, Veith T, Schneider J, Beheim-Schwarzbach J, Bleicker
957 T, Tesch J, Schmidt ML, Sander LE, Kurth F, Menzel P, Schwarzer R, Zuchowski
958 M, Hofmann J, Krumbholz A, Stein A, Edelmann A, Corman VM, Drosten C. 2021.
959 Estimating infectiousness throughout SARS-CoV-2 infection course. *Science*
960 **373**:eabi5273.

961 Karlberg J. 2004. Do Men Have a Higher Case Fatality Rate of Severe Acute Respiratory
962 Syndrome than Women Do? *American Journal of Epidemiology*.
963 doi:10.1093/aje/kwh056

964 Kassambara A. 2020. ggpubr: “ggplot2” Based Publication Ready Plots.

965 Klein SL, Flanagan KL. 2016. Sex differences in immune responses. *Nat Rev Immunol*
966 **16**:626–638.

967 Klose CSN, Artis D. 2016. Innate lymphoid cells as regulators of immunity, inflammation
968 and tissue homeostasis. *Nat Immunol* **17**:765–774.

969 Kløverpris HN, Kazer SW, Mjösberg J, Mabuka JM, Wellmann A, Ndhlovu Z, Yadon MC,
970 Nhamoyebonde S, Muenchhoff M, Simoni Y, Andersson F, Kuhn W, Garrett N,
971 Burgers WA, Kamya P, Pretorius K, Dong K, Moodley A, Newell EW, Kasproicz
972 V, Abdool Karim SS, Goulder P, Shalek AK, Walker BD, Ndung'u T, Leslie A. 2016.
973 Innate Lymphoid Cells Are Depleted Irreversibly during Acute HIV-1 Infection in
974 the Absence of Viral Suppression. *Immunity* **44**:391–405.

975 Kompaniyets L. 2021. Body Mass Index and Risk for COVID-19–Related Hospitalization,
976 Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death —
977 United States, March–December 2020. *MMWR Morb Mortal Wkly Rep* **70**.
978 doi:10.15585/mmwr.mm7010e4

979 Kuri-Cervantes L, Pampera MB, Meng W, Rosenfeld AM, Ittner CAG, Weisman AR,
980 Agyekum RS, Mathew D, Baxter AE, Vella LA, Kuthuru O, Apostolidis SA, Bershaw
981 L, Dougherty J, Greenplate AR, Pattekar A, Kim J, Han N, Gouma S, Weirick ME,
982 Arevalo CP, Bolton MJ, Goodwin EC, Anderson EM, Hensley SE, Jones TK,
983 Mangalmurti NS, Luning Prak ET, Wherry EJ, Meyer NJ, Betts MR. 2020.
984 Comprehensive mapping of immune perturbations associated with severe COVID-
985 19. *Sci Immunol* **5**:eabd7114.

986 Kuznetsova A, Brockhoff PB, Christensen RHB, Others. 2017. lmerTest package: tests
987 in linear mixed effects models. *J Stat Softw* **82**:1–26.

988 Laxminarayan R, Wahl B, Dudala SR, Gopal K, Mohan B C, Neelima S, Jawahar Reddy
989 KS, Radhakrishnan J, Lewnard JA. 2020. Epidemiology and transmission
990 dynamics of COVID-19 in two Indian states. *Science* **370**:691–697.

991 Lee S, Kim T, Lee E, Lee C, Kim H, Rhee H, Park SY, Son H-J, Yu S, Park JW, Choo EJ,
992 Park S, Loeb M, Kim TH. 2020. Clinical Course and Molecular Viral Shedding
993 Among Asymptomatic and Symptomatic Patients With SARS-CoV-2 Infection in a
994 Community Treatment Center in the Republic of Korea. *JAMA Internal Medicine*
995 **180**:1447.

996 Leist SR, Dinno KH 3rd, Schäfer A, Tse LV, Okuda K, Hou YJ, West A, Edwards CE,
997 Sanders W, Fritch EJ, Gully KL, Scobey T, Brown AJ, Sheahan TP, Moorman NJ,
998 Boucher RC, Gralinski LE, Montgomery SA, Baric RS. 2020. A Mouse-Adapted
999 SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory
1000 Mice. *Cell* **183**:1070-1085.e12.

1001 Lennon NJ, Bhattacharyya RP, Mina MJ, Rehm HL, Hung DT, Smole S, Woolley A,
1002 Lander ES, Gabriel SB. 2021. Cross-sectional assessment of SARS-CoV-2 viral
1003 load by symptom status in Massachusetts congregate living facilities. *J Infect Dis.*
1004 doi:10.1093/infdis/jiab367

1005 Lennon NJ, Bhattacharyya RP, Mina MJ, Rehm HL, Hung DT, Smole S, Woolley A,
1006 Lander ES, Gabriel SB. 2020. Comparison of viral levels in individuals with or
1007 without symptoms at time of COVID-19 testing among 32,480 residents and staff
1008 of nursing homes and assisted living facilities in Massachusetts. *bioRxiv.*
1009 doi:10.1101/2020.07.20.20157792

1010 Lenth R. 2020. emmeans: Estimated Marginal Means, aka Least-Squares Means.

1011 Li B, Dewey CN. 2011. RSEM: accurate transcript quantification from RNA-Seq data with
1012 or without a reference genome. *BMC Bioinformatics* **12**:323.

1013 Li B, Zhang S, Zhang R, Chen X, Wang Y, Zhu C. 2020. Epidemiological and Clinical
1014 Characteristics of COVID-19 in Children: A Systematic Review and Meta-Analysis.
1015 *Front Pediatr* **8**:591132.

1016 Licciardi F, Pruccoli G, Denina M, Parodi E, Taglietto M, Rosati S, Montin D. 2020. SARS-
1017 CoV-2-Induced Kawasaki-Like Hyperinflammatory Syndrome: A Novel COVID
1018 Phenotype in Children. *Pediatrics*. doi:10.1542/peds.2020-1711

1019 López-Otín C, Kroemer G. 2021. Hallmarks of Health. *Cell* **184**:33–63.

1020 LoTempio JE, Billings EA, Draper K, Ralph C, Moshgriz M, Duong N, Bard JD, Gai X,
1021 Wessel D, DeBiasi RL, Campos JM, Vilain E, Delaney M, Michael DG. 2021. Novel
1022 SARS-CoV-2 spike variant identified through viral genome sequencing of the
1023 pediatric Washington D.C. COVID-19 outbreak. *medRxiv* 2021.02.08.21251344.

1024 Love M, Anders S, Huber W. 2014. Differential analysis of count data--the DESeq2
1025 package. *Genome Biol* **15**:550.

1026 Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, Zhang W, Wang Y, Bao S, Li Y, Wu C, Liu H,
1027 Liu D, Shao J, Peng X, Yang Y, Liu Z, Xiang Y, Zhang F, Silva RM, Pinkerton KE,
1028 Shen K, Xiao H, Xu S, Wong GWK, Chinese Pediatric Novel Coronavirus Study
1029 Team. 2020. SARS-CoV-2 Infection in Children. *N Engl J Med* **382**:1663–1665.

1030 Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, Ellingson MK, Mao T, Oh
1031 JE, Israelow B, Takahashi T, Tokuyama M, Lu P, Venkataraman A, Park A,
1032 Mohanty S, Wang H, Wyllie AL, Vogels CBF, Earnest R, Lapidus S, Ott IM, Moore
1033 AJ, Muenker MC, Fournier JB, Campbell M, Odio CD, Casanovas-Massana A,

1034 Yale IMPACT Team, Herbst R, Shaw AC, Medzhitov R, Schulz WL, Grubaugh ND,
1035 Dela Cruz C, Farhadian S, Ko AI, Omer SB, Iwasaki A. 2020. Longitudinal
1036 analyses reveal immunological misfiring in severe COVID-19. *Nature* **584**:463–
1037 469.

1038 Luo X, Zhou W, Yan X, Guo T, Wang B, Xia H, Ye L, Xiong J, Jiang Z, Liu Y, Zhang B,
1039 Yang W. 2020. Prognostic Value of C-Reactive Protein in Patients With
1040 Coronavirus 2019. *Clin Infect Dis* **71**:2174–2179.

1041 Márquez EJ, Chung C-H, Marches R, Rossi RJ, Nehar-Belaid D, Eroglu A, Mellert DJ,
1042 Kuchel GA, Banchereau J, Ucar D. 2020. Sexual-dimorphism in human immune
1043 system aging. *Nat Commun* **11**:751.

1044 Mathew D, Giles JR, Baxter AE, Oldridge DA, Greenplate AR, Wu JE, Alanio C, Kuri-
1045 Cervantes L, Pampena MB, D'Andrea K, Manne S, Chen Z, Huang YJ, Reilly JP,
1046 Weisman AR, Ittner CAG, Kuthuru O, Dougherty J, Nzingha K, Han N, Kim J,
1047 Pattekar A, Goodwin EC, Anderson EM, Weirick ME, Gouma S, Arevalo CP,
1048 Bolton MJ, Chen F, Lacey SF, Ramage H, Cherry S, Hensley SE, Apostolidis SA,
1049 Huang AC, Vella LA, UPenn COVID Processing Unit, Betts MR, Meyer NJ, Wherry
1050 EJ. 2020. Deep immune profiling of COVID-19 patients reveals distinct
1051 immunotypes with therapeutic implications. *Science* **369**.
1052 doi:10.1126/science.abc8511

1053 Mauvais-Jarvis F. 2020. Aging, Male Sex, Obesity, and Metabolic Inflammation Create
1054 the Perfect Storm for COVID-19. *Diabetes* **69**:1857–1863.

1055 McCarville JL, Ayres JS. 2018. Disease tolerance: concept and mechanisms. *Curr Opin*
1056 *Immunol* **50**:88–93.

1057 Medzhitov R, Schneider DS, Soares MP. 2012. Disease tolerance as a defense strategy.
1058 *Science* **335**:936–941.

1059 Monticelli LA, Osborne LC, Noti M, Tran SV, Zaiss DMW, Artis D. 2015. IL-33 promotes
1060 an innate immune pathway of intestinal tissue protection dependent on
1061 amphiregulin–EGFR interactions. *Proc Natl Acad Sci U S A* **112**:10762–10767.

1062 Monticelli LA, Sonnenberg GF, Abt MC, Alenghat T, Ziegler CGK, Doering TA,
1063 Angelosanto JM, Laidlaw BJ, Yang CY, Sathaliyawala T, Kubota M, Turner D,
1064 Diamond JM, Goldrath AW, Farber DL, Collman RG, Wherry EJ, Artis D. 2011.
1065 Innate lymphoid cells promote lung-tissue homeostasis after infection with
1066 influenza virus. *Nat Immunol* **12**:1045–1054.

1067 Mudd PA, Crawford JC, Turner JS, Souquette A, Reynolds D, Bender D, Bosanquet JP,
1068 Anand NJ, Striker DA, Martin RS, Boon ACM, House SL, Remy KE, Hotchkiss RS,
1069 Presti RM, O'Halloran JA, Powderly WG, Thomas PG, Ellebedy AH. 2020. Distinct
1070 inflammatory profiles distinguish COVID-19 from influenza with limited
1071 contributions from cytokine storm. *Sci Adv* **6**. doi:10.1126/sciadv.abe3024

1072 O'Driscoll M, Ribeiro Dos Santos G, Wang L, Cummings DAT, Azman AS, Paireau J,
1073 Fontanet A, Cauchemez S, Salje H. 2020. Age-specific mortality and immunity
1074 patterns of SARS-CoV-2. *Nature*. doi:10.1038/s41586-020-2918-0

1075 Patin E, Hasan M, Bergstedt J, Rouilly V, Libri V, Urrutia A, Alanio C, Scepianovic P,
1076 Hammer C, Jönsson F, Beitz B, Quach H, Lim YW, Hunkapiller J, Zepeda M,
1077 Green C, Piasecka B, Leloup C, Rogge L, Huetz F, Peguillet I, Lantz O, Fontes M,
1078 Di Santo JP, Thomas S, Fellay J, Duffy D, Quintana-Murci L, Albert ML, Milieu

1079 Intérieur Consortium. 2018. Natural variation in the parameters of innate immune
1080 cells is preferentially driven by genetic factors. *Nat Immunol* **19**:302–314.

1081 Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR,
1082 Rosser EC, Webb K, Deakin CT. 2020. Male sex identified by global COVID-19
1083 meta-analysis as a risk factor for death and ITU admission. *Nature*
1084 *Communications* **11**:6317.

1085 Piasecka B, Duffy D, Urrutia A, Quach H, Patin E, Posseme C, Bergstedt J, Charbit B,
1086 Rouilly V, MacPherson CR, Hasan M, Albaud B, Gentien D, Fellay J, Albert ML,
1087 Quintana-Murci L, Milieu Intérieur Consortium. 2018. Distinctive roles of age, sex,
1088 and genetics in shaping transcriptional variation of human immune responses to
1089 microbial challenges. *Proc Natl Acad Sci U S A* **115**:E488–E497.

1090 Poline J, Gaschignard J, Leblanc C, Madhi F, Foucaud E, Nattes E, Faye A, Bonacorsi
1091 S, Mariani P, Varon E, Smati-Lafarge M, Caseris M, Basmaci R, Lachaume N,
1092 Ouldali N. 2020. Systematic SARS-CoV-2 screening at hospital admission in
1093 children: a French prospective multicenter study. *Clin Infect Dis*.
1094 doi:10.1093/cid/ciaa1044

1095 R Core Team. 2020. R: A Language and Environment for Statistical Computing.

1096 Ra SH, Lim JS, Kim G-U, Kim MJ, Jung J, Kim S-H. 2021. Upper respiratory viral load in
1097 asymptomatic individuals and mildly symptomatic patients with SARS-CoV-2
1098 infection. *Thorax* **76**:61–63.

1099 Råberg L, Sim D, Read AF. 2007. Disentangling genetic variation for resistance and
1100 tolerance to infectious diseases in animals. *Science* **318**:812–814.

1101 Rak GD, Osborne LC, Siracusa MC, Kim BS, Wang K, Bayat A, Artis D, Volk SW. 2016.
 1102 IL-33-Dependent Group 2 Innate Lymphoid Cells Promote Cutaneous Wound
 1103 Healing. *J Invest Dermatol* **136**:487–496.

1104 Rauber S, Lubber M, Weber S, Maul L, Soare A, Wohlfahrt T, Lin N-Y, Dietel K, Bozec A,
 1105 Herrmann M, Kaplan MH, Weigmann B, Zaiss MM, Fearon U, Veale DJ, Cañete
 1106 JD, Distler O, Rivellese F, Pitzalis C, Neurath MF, McKenzie ANJ, Wirtz S, Schett
 1107 G, Distler JHW, Ramming A. 2017. Resolution of inflammation by interleukin-9-
 1108 producing type 2 innate lymphoid cells. *Nat Med* **23**:938–944.

1109 Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, the
 1110 Northwell COVID-19 Research Consortium, Barnaby DP, Becker LB, Chelico JD,
 1111 Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefe
 1112 J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM,
 1113 Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP. 2020. Presenting
 1114 Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized
 1115 With COVID-19 in the New York City Area. *JAMA* **323**:2052–2059.

1116 Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. 2020.
 1117 Hyperinflammatory shock in children during COVID-19 pandemic. *Lancet*.

1118 Sanchez KK, Chen GY, Schieber AMP, Redford SE, Shokhirev MN, Leblanc M, Lee YM,
 1119 Ayres JS. 2018. Cooperative Metabolic Adaptations in the Host Can Favor
 1120 Asymptomatic Infection and Select for Attenuated Virulence in an Enteric
 1121 Pathogen. *Cell* **175**:146-158.e15.

1122 Sancho-Shimizu V, Brodin P, Cobat A, Biggs CM, Toubiana J, Lucas CL, Henrickson SE,
 1123 Belot A, MIS-C@CHGE, Tangye SG, Milner JD, Levin M, Abel L, Bogunovic D,

1124 Casanova J-L, Zhang S-Y. 2021. SARS-CoV-2–related MIS-C: A key to the viral
1125 and genetic causes of Kawasaki disease? *J Exp Med* **218**.
1126 doi:10.1084/jem.20210446

1127 Schneider DS, Ayres JS. 2008. Two ways to survive infection: what resistance and
1128 tolerance can teach us about treating infectious diseases. *Nature Reviews*
1129 *Immunology* **8**:889–895.

1130 Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. 2020. Considering how
1131 biological sex impacts immune responses and COVID-19 outcomes. *Nat Rev*
1132 *Immunol* **20**:442–447.

1133 Solana R, Tarazona R, Gayoso I, Lesur O, Dupuis G, Fulop T. 2012. Innate
1134 immunosenescence: effect of aging on cells and receptors of the innate immune
1135 system in humans. *Semin Immunol* **24**:331–341.

1136 Tesoriero JM, Swain C-AE, Pierce JL, Zamboni L, Wu M, Holtgrave DR, Gonzalez CJ,
1137 Udo T, Morne JE, Hart-Malloy R, Rajulu DT, Leung S-YJ, Rosenberg ES. 2021.
1138 COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV
1139 Infection in New York State. *JAMA Netw Open* **4**:e2037069.

1140 Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, Bonanomi E,
1141 D’Antiga L. 2020. An outbreak of severe Kawasaki-like disease at the Italian
1142 epicentre of the SARS-CoV-2 epidemic: an observational cohort study. *Lancet*
1143 **395**:1771–1778.

1144 Vivier E, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, Koyasu S, Locksley
1145 RM, McKenzie ANJ, Mebius RE, Powrie F, Spits H. 2018. Innate Lymphoid Cells:
1146 10 Years On. *Cell* **174**:1054–1066.

1147 Wang A, Huen SC, Luan HH, Yu S, Zhang C, Gallezot J-D, Booth CJ, Medzhitov R. 2016.
1148 Opposing Effects of Fasting Metabolism on Tissue Tolerance in Bacterial and Viral
1149 Inflammation. *Cell* **166**:1512-1525.e12.

1150 Wang Y, Lifshitz L, Gellatly K, Vinton CL, Busman-Sahay K, McCauley S, Vangala P, Kim
1151 K, Derr A, Jaiswal S, Kucukural A, McDonel P, Hunt PW, Greenough T, Houghton
1152 J, Somsouk M, Estes JD, Brenchley JM, Garber M, Deeks SG, Luban J. 2020.
1153 HIV-1-induced cytokines deplete homeostatic innate lymphoid cells and expand
1154 TCF7-dependent memory NK cells. *Nat Immunol* **21**:274–286.

1155 Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah P, Ramnarayan P, Fraisse
1156 A, Miller O, Davies P, Kucera F, Brierley J, McDougall M, Carter M, Tremoulet A,
1157 Shimizu C, Herberg J, Burns JC, Lyall H, Levin M, PIMS-TS Study Group and
1158 EUCLIDS and PERFORM Consortia. 2020. Clinical Characteristics of 58 Children
1159 With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With
1160 SARS-CoV-2. *JAMA* **324**:259–269.

1161 Wickham H. 2016. ggplot2: Elegant Graphics for Data Analysis. Springer.

1162 Wickham H, Averick M, Bryan J, Chang W, McGowan L, François R, Golemund G, Hayes
1163 A, Henry L, Hester J, Kuhn M, Pedersen T, Miller E, Bache S, Müller K, Ooms J,
1164 Robinson D, Seidel D, Spinu V, Takahashi K, Vaughan D, Wilke C, Woo K, Yutani
1165 H. 2019. Welcome to the Tidyverse. *JOSS* **4**:1686.

1166 Yang Q, Monticelli LA, Saenz SA, Chi AW-S, Sonnenberg GF, Tang J, De Obaldia ME,
1167 Bailis W, Bryson JL, Toscano K, Huang J, Haczku A, Pear WS, Artis D, Bhandoola
1168 A. 2013. T cell factor 1 is required for group 2 innate lymphoid cell generation.
1169 *Immunity* **38**:694–704.

1170 Yang Q, Saldi TK, Gonzales PK, Lasda E, Decker CJ, Tat KL, Fink MR, Hager CR, Davis
1171 JC, Ozeroff CD, Muhlrud D, Clark SK, Fattor WT, Meyerson NR, Paige CL,
1172 Gilchrist AR, Barbachano-Guerrero A, Worden-Sapper ER, Wu SS, Brisson GR,
1173 McQueen MB, Dowell RD, Leinwand L, Parker R, Sawyer SL. 2021. Just 2% of
1174 SARS-CoV-2-positive individuals carry 90% of the virus circulating in
1175 communities. *Proc Natl Acad Sci U S A* **118**. doi:10.1073/pnas.2104547118

1176 Yonker LM, Gilboa T, Ogata AF, Senussi Y, Lazarovits R, Boribong BP, Bartsch YC,
1177 Loiselle M, Noval Rivas M, Porritt RA, Lima R, Davis JP, Farkas EJ, Burns MD,
1178 Young N, Mahajan VS, Hajizadeh S, Herrera Lopez XI, Kreuzer J, Morris R,
1179 Martinez EE, Han I, Griswold K Jr, Barry NC, Thompson DB, Church G, Edlow AG,
1180 Haas W, Pillai S, Arditi M, Alter G, Walt DR, Fasano A. 2021. Multisystem
1181 inflammatory syndrome in children is driven by zonulin-dependent loss of gut
1182 mucosal barrier. *J Clin Invest*. doi:10.1172/JCI149633

1183 Yonker LM, Neilan AM, Bartsch Y, Patel AB, Regan J, Arya P, Gootkind E, Park G,
1184 Hardcastle M, St John A, Appleman L, Chiu ML, Fialkowski A, De la Flor D, Lima
1185 R, Bordt EA, Yockey LJ, D'Avino P, Fischinger S, Shui JE, Lerou PH, Bonventre
1186 JV, Yu XG, Ryan ET, Bassett IV, Irimia D, Edlow AG, Alter G, Li JZ, Fasano A.
1187 2020. Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-
1188 2): Clinical Presentation, Infectivity, and Immune Responses. *J Pediatr* **227**:45-
1189 52.e5.

1190 Yu G, Wang L-G, Han Y, He Q-Y. 2012. clusterProfiler: an R Package for Comparing
1191 Biological Themes Among Gene Clusters. *OMICS* **16**:284–287.

1192 Yudanin NA, Schmitz F, Flamar A-L, Thome JJC, Tait Wojno E, Moeller JB, Schirmer M,
1193 Latorre IJ, Xavier RJ, Farber DL, Monticelli LA, Artis D. 2019. Spatial and Temporal
1194 Mapping of Human Innate Lymphoid Cells Reveals Elements of Tissue Specificity.
1195 *Immunity* **50**:505-519.e4.

1196 Yukselen O, Turkeyilmaz O, Ozturk AR, Garber M, Kucukural A. 2020. DolphinNext: a
1197 distributed data processing platform for high throughput genomics. *BMC*
1198 *Genomics* **21**:310.

1199 Zhang Z-L, Hou Y-L, Li D-T, Li F-Z. 2020. Laboratory findings of COVID-19: a systematic
1200 review and meta-analysis. *Scand J Clin Lab Invest* **80**:441–447.

1201 Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Deng Y, Weng Z, Yang L. 2020.
1202 Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19)
1203 infections: A systemic review and meta-analysis. *Int J Infect Dis* **96**:131–135.

1204 Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, Xu Y, Tian Z. 2020. Functional
1205 exhaustion of antiviral lymphocytes in COVID-19 patients. *Cell Mol Immunol*.

1206 Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei
1207 Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. 2020. Clinical course and risk
1208 factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a
1209 retrospective cohort study. *Lancet* **395**:1054–1062.

1210

1211

1212

1213

1214

ACKNOWLEDGEMENTS

We thank the Massachusetts Consortium for Pathogen Readiness Specimen Collection and Processing Team listed below and members of the Yu and Luban Labs. This work was supported in part by the Massachusetts Consortium for Pathogen Readiness through grants from the Evergrande Fund and NIH grants R37AI147868 and R01AI148784 to J.L. and Ruth L. Kirschstein NRSA Fellowship F30HD100110 to N.J.S. The MGH/MassCPR COVID biorepository was supported by a gift from Ms. Enid Schwartz, by the Mark and Lisa Schwartz Foundation, the Massachusetts Consortium for Pathogen Readiness, and the Ragon Institute of MGH, MIT and Harvard. The Pediatric COVID-19 Biorepository was supported by the National Heart, Lung, and Blood Institute (5K08HL143183 to LMY), and the Department of Pediatrics at Massachusetts General Hospital *for* Children (to LMY).

MGH COVID-19 Collection & Processing Team participants Collection Team:

Kendall Lavin-Parsons¹, Blair Parry¹, Brendan Lilley¹, Carl Lodenstein¹, Brenna McKaig¹, Nicole Charland¹, Hargun Khanna¹, Justin Margolin¹

Processing Team: Anna Gonye², Irena Gushterova², Tom Lasalle², Nihaarika Sharma², Brian C. Russo³, Maricarmen Rojas-Lopez³, Moshe Sade-Feldman⁴, Kasidet Manakongtreecheep⁴, Jessica Tantivit⁴, Molly Fisher Thomas⁴

Massachusetts Consortium on Pathogen Readiness: Betelihem A. Abayneh⁵, Patrick Allen⁵, Diane Antille⁵, Katrina Armstrong⁵, Siobhan Boyce⁵, Joan Braley⁵, Karen Branch⁵, Katherine Broderick⁵, Julia Carney⁵, Andrew Chan⁵, Susan Davidson⁵, Michael Dougan⁵, David Drew⁵, Ashley Elliman⁵, Keith Flaherty⁵, Jeanne Flannery⁵, Pamela Forde⁵, Elise Gettings⁵, Amanda Griffin⁵, Sheila Grimmel⁵, Kathleen Grinke⁵, Kathryn Hall⁵, Meg

1238 Healy⁵, Deborah Henault⁵, Grace Holland⁵, Chantal Kayitesi⁵, Vlasta LaValle⁵, Yuting Lu⁵,
 1239 Sarah Luthern⁵, Jordan Marchewka (Schneider)⁵, Brittani Martino⁵, Roseann
 1240 McNamara⁵, Christian Nambu⁵, Susan Nelson⁵, Marjorie Noone⁵, Christine Ommerborn⁵,
 1241 Lois Chris Pacheco⁵, Nicole Phan⁵, Falisha A. Porto⁵, Edward Ryan⁵, Kathleen Selleck⁵,
 1242 Sue Slaughenhaupt⁵, Kimberly Smith Sheppard⁵, Elizabeth Suschana⁵, Vivine Wilson⁵,
 1243 Galit Alter⁶, Alejandro Balazs⁶, Julia Bals⁶, Max Barbash⁶, Yannic Bartsch⁶, Julie
 1244 Boucau⁶, Josh Chevalier⁶, Fatema Chowdhury⁶, Kevin Einkauf⁶, Jon Fallon⁶, Liz Fedirko⁶,
 1245 Kelsey Finn⁶, Pilar Garcia-Broncano⁶, Ciputra Hartana⁶, Chenyang Jiang⁶, Paulina
 1246 Kaplonek⁶, Marshall Karpell⁶, Evan C. Lam⁶, Kristina Lefteri⁶, Xiaodong Lian⁶, Mathias
 1247 Lichterfeld⁶, Daniel Lingwood⁶, Hang Liu⁶, Jinqing Liu⁶, Natasha Ly⁶, Ashlin Michell⁶, Ilan
 1248 Millstrom⁶, Noah Miranda⁶, Claire O'Callaghan⁶, Matthew Osborn⁶, Shiv Pillai⁶, Yelizaveta
 1249 Rassadkina⁶, Alexandra Reissis⁶, Francis Ruzicka⁶, Kyra Seiger⁶, Libera Sessa⁶,
 1250 Christianne Sharr⁶, Sally Shin⁶, Nishant Singh⁶, Weiwei Sun⁶, Xiaoming Sun⁶, Hannah
 1251 Ticheli⁶, Alicja Trocha-Piechocka⁶, Daniel Worrall⁶, Alex Zhu⁶, George Daley⁷, David
 1252 Golan⁷, Howard Heller⁷, Arlene Sharpe⁷, Nikolaus Jilg⁸, Alex Rosenthal⁸, Colline Wong⁸

1253
 1254 ¹Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA,
 1255 USA.

1256 ²Massachusetts General Hospital Cancer Center, Boston, MA, USA.

1257 ³Division of Infectious Diseases, Department of Medicine, Massachusetts General
 1258 Hospital, Boston, MA, USA.

1259 ⁴Massachusetts General Hospital Center for Immunology and Inflammatory Diseases,
 1260 Boston, MA, USA.

1261 ⁵Massachusetts General Hospital, Boston, MA, USA.

1262 ⁶Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.

1263 ⁷Harvard Medical School, Boston, MA, USA.

1264 ⁸Brigham and Women's Hospital, Boston, MA, USA.

1265

1266 **Author information**

1267 Correspondence and requests for materials should be addressed to J.L.

1268 (jeremy.luban@umassmed.edu).